At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 256 enrolled
Drug / intervention
Brensocatib 10 mg +2 moredrug
Likely dose
Brensocatib 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
In Brief
A Phase 2 clinical trial evaluating Brensocatib 10 mg, Brensocatib 25 mg, and 1 other intervention for Non-Cystic Fibrosis Bronchiectasis. Completed, enrolled 256 participants across 108 sites in 14 countries.
Detailed Summary
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Cystic Fibrosis Bronchiectasis
CountriesAustralia, Belgium, Bulgaria, Denmark, Germany, Italy, Netherlands, New Zealand, Poland, Singapore, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartOct 2017
Primary CompletionDec 2019
TodayJul 2026
First PostedJul 17, 2017
Enrollment StartOct 31, 2017
Primary CompletionDec 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.0 years ago
Interventions
Brensocatib 10 mgdrug
Administered once per day for 24 weeks
Brensocatib 25 mgdrug
Administered once per day for 24 weeks
Placebodrug
Administered once per day for 24 weeks